ARL6IP1 Inhibits Breast Cancer Tumor Progression by Targeting OLFM4 to Regulate Glycolysis
ARL6IP1 is a critical regulator of BC progression, influencing glycolysis, mitochondrial function, and key cellular behaviors. Targeting the ARL6IP1-OLFM4 axis offers a promising therapeutic strategy for managing BC.
Authors
- Fei Gu (ORCID: https://orcid.org/0000-0002-7725-3909)
- Lijun Zhou (ORCID: https://orcid.org/0000-0002-9787-8295)
- Lingping Zhu (ORCID: https://orcid.org/0000-0001-5773-736X)
- Chen Chen (ORCID: https://orcid.org/0000-0002-8668-5391)
Institutions
- Fudan University (CN)
- Huashan Hospital (CN)
Publication Details
- Journal
- Combinatorial Chemistry & High Throughput Screening
- Published
- 2025-05-30
- DOI
- https://doi.org/10.2174/0113862073358595250211053816
- Primary Topic
- Inflammatory mediators and NSAID effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00